RSS   Newsletter   Contact   Advertise with us
Post Online Media

Orexigen Therapeutics appoints Deborah A. Jorn to board

Orexigen TherapeuticsOrexigen Therapeutics, a biotechnology company, announced the appointment of Deborah A. Jorn to its board of directors.

Ms. Jorn is a senior commercial strategist with a more than 30 year of experience. She is the former Executive Vice President and Group Company Chair at Valeant Pharmaceuticals and was responsible for Valeant's two largest business units, Dermatology and Gastroenterology, and led a marketing and sales organization.

Article continues below

READ MORE Orexigen Therapeutics appoints Peter Honig, M.D. to the board

Prior to Valeant, Ms. Jorn was the Chief Global Marketing Officer at Bausch and Lomb Pharmaceuticals and served as the commercial head of their Global Pharmaceutical Division. She also served in senior commercial leadership roles at Schering Plough, Johnson & Johnson, and Pharmacia.

Ms. Jorn received a MBA from the Stern Graduate School of Business Administration at New York University and a BA in Biochemistry from Rutgers University.


More inside POST

We use cookies to ensure that we give you the best experience on our website. Please allow cookies for fully-functioning website.

Allow Cookies Privacy Policy